m (Changed dosage table to use api)
 
(13 intermediate revisions by 4 users not shown)
Line 1: Line 1:
 
[[File:25c.jpg|thumb|300px|25C-NBOMe tabs dosed at 1mg each.]]
 
[[File:25c.jpg|thumb|300px|25C-NBOMe tabs dosed at 1mg each.]]
  
These chemicals have nearly no history of human use prior to 2010 when they first became available online, and very little is known about this group of compounds. They should only be used with extreme caution. It's recommended to not take more than 1.5 mg of any substance of the NBOMe family, as there have been multiple deaths from people just taking 2-3 blotters.
+
These chemicals have nearly no history of human use prior to 2010 when they first became available online, and very little is known about this group of compounds. They should only be used with extreme caution. It's strongly recommended to not take more than 1500 µg of any substance of the NBOMe family, as there have been multiple deaths from people taking just 2-3 blotters.
  
= Dosages =  
+
== Dosage ==  
Effects have been reported to vary very strongly by person (example: person A gets a 4-hour body high with barely any visual aspects, while person B gets a >12 hour DOB-like trip with an intense visual aspect).
+
Effects have been reported to vary wildly between people (example: person A gets a 4-hour body high with barely any visual aspects, while person B gets a >12 hour DOB-like trip with an intense visual aspect). Drugs affect all users differently, but this unusually wide range of reported effects is down, in part, to users being unable to accurately distinguish between members of the NBOMe series, and misrepresentation of doses - a single tab regularly yields between 500ug and 2000ug of the substance.
  
NBOMes are often thought to be orally inactive, meaning they wouldn't work if swallowed. However, this is not the case for all NBOMes per se; certain salts do have an oral bioavailability. Therefore, when a substance might be an NBOMe, discard the blotter entirely rather than swallowing it, if you wish not to be under the influence of an NBOMe substance. Oral administration is relatively uncommon and thus undocumented as a result of the existing misconception. Sublingual administration is more common, but buccal administration is recommended if you wish to avoid the generally bitter taste of NBOMes.
+
NBOMes were initially thought to be orally inactive, meaning they wouldn't work if swallowed. However, this is not the case for all NBOMes per se; certain NBOMe salts do have an observed oral bioavailability, with little known about the oral bioavailability of NBOMes in their freebase form. Therefore, when a substance might be an NBOMe, discard the blotter entirely rather than swallowing it, if you do not wish to risk being under the influence of an NBOMe. Oral administration is relatively uncommon and thus undocumented, presumably as a result of the existing confusion about the oral bioavailability of NBOMes. Sublingual administration is the most common, but buccal administration is recommended if you wish to avoid the generally bitter taste of NBOMes.
  
== 25I-NBOMe ==
+
The doses of NBOMes remain a controversial subject, as deaths have been reported at doses that were previously assumed acceptable. Please use caution, and in any case, '''do not exceed 1500µg'''!
  
{| class="wikitable"
+
=== 25B-NBOMe ===  
|+ Sublingual
+
|-
+
| Light || 200-500 μg
+
|-
+
| Common || 500-1500 μg
+
|-
+
| Strong || 1500+ μg
+
|}
+
 
+
{| class="wikitable"
+
|+ Insufflated
+
|-
+
| Light || 100-400 μg
+
|-
+
| Common || 400-700 μg
+
|-
+
| Strong || 700+ μg+
+
|}
+
  
== 25C-NBOMe ==
+
{{#tdose: 25B-NBOMe}}
  
Effects have been reported to vary very strongly by person (for example: person A gets a 4-hour body high with barely any visual aspects, while person B gets a >12 hour DOB-like trip with an intense visual aspect).
+
=== 25C-NBOMe ===
  
 
{| class="wikitable"
 
{| class="wikitable"
Line 44: Line 26:
 
|}
 
|}
  
== 25B-NBOMe ==  
+
=== 25I-NBOMe ===
  
 
{| class="wikitable"
 
{| class="wikitable"
 
|+ Sublingual
 
|+ Sublingual
 
|-
 
|-
| Light || 100-300 μg
+
| Light || 200-500 μg
 
|-
 
|-
| Common || 300-500 μg
+
| Common || 500-750 μg
 
|-
 
|-
| Strong || 500-700+ μg
+
| Strong || 700-1000+ μg
 
|}
 
|}
  
Line 59: Line 41:
 
|+ Insufflated
 
|+ Insufflated
 
|-
 
|-
| Light || 50-200 μg
+
| Light || 100-400 μg
 
|-
 
|-
| Common || 200-350 μg
+
| Common || 400-700 μg
 
|-
 
|-
| Strong || 350-500+ μg
+
| Strong || 700+ μg
 
|}
 
|}
  
= Duration =
+
== Duration ==
  
 
{| class="wikitable"
 
{| class="wikitable"
Line 84: Line 66:
 
|}
 
|}
  
= Effects =
+
== Effects ==
  
== Positive ==
+
=== Positive ===
  
 
* Strong open and closed eye visuals, including trails, color shifts, brightening, etc.
 
* Strong open and closed eye visuals, including trails, color shifts, brightening, etc.
Line 98: Line 80:
 
* Feelings of love and empathy
 
* Feelings of love and empathy
  
== Neutral ==
+
=== Neutral ===
  
 
* General change in consciousness
 
* General change in consciousness
Line 108: Line 90:
 
* Yawning, especially when coming up
 
* Yawning, especially when coming up
  
== Negative ==
+
=== Negative ===
  
 
Likelihood of negative side effects increases with higher doses.
 
Likelihood of negative side effects increases with higher doses.
Line 122: Line 104:
 
* Unwanted life-changing spiritual experiences
 
* Unwanted life-changing spiritual experiences
  
== After effects ==
+
=== After effects ===
  
 
* Afterglow
 
* Afterglow
Line 130: Line 112:
 
**A relatively high rate of HPPD has been reported (all anecdotal data!) after the use of the NBOMe chemicals.
 
**A relatively high rate of HPPD has been reported (all anecdotal data!) after the use of the NBOMe chemicals.
  
= Harm Reduction =
+
== Harm Reduction ==
  
 
NBOMes are considered less safe than many psychedelics due their heavy physical effects on the body, and as recreational dosages tend to overlap with what have been fatal dosages. Even so, many reports of death by an NBOMe chemical involve mislabeling of the drug, sometimes by the distributor (example: someone insufflates 20mg of 25I-NBOMe because he/she thought it was 2C-I). Mislabeling or misweighing can easily lead to extrememely dangerous, sometimes lethal, situations. Administration of an NBOMe in its powder form (either insufflated or otherwise) is strongly discouraged, as the potency is far greater than the accuracy of most scales.
 
NBOMes are considered less safe than many psychedelics due their heavy physical effects on the body, and as recreational dosages tend to overlap with what have been fatal dosages. Even so, many reports of death by an NBOMe chemical involve mislabeling of the drug, sometimes by the distributor (example: someone insufflates 20mg of 25I-NBOMe because he/she thought it was 2C-I). Mislabeling or misweighing can easily lead to extrememely dangerous, sometimes lethal, situations. Administration of an NBOMe in its powder form (either insufflated or otherwise) is strongly discouraged, as the potency is far greater than the accuracy of most scales.
Line 138: Line 120:
 
See [[Psychedelics#Harm_Reduction|Psychedelic Harm Reduction]] for general information.
 
See [[Psychedelics#Harm_Reduction|Psychedelic Harm Reduction]] for general information.
  
= Legal status =
+
== Images ==
  
== Europe ==
+
<gallery mode="packed-hover" heights="150px">
 +
Image:25b.jpg|''25B-NBOMe''
 +
Image:25c.jpg|''25C-NBOMe''
 +
Image:25i.jpg|''25I-NBOMe''
 +
</gallery>
 +
 
 +
 
 +
== Legal status ==
 +
 
 +
=== Europe ===
  
 
The NBOMe series of psychoactives became controlled in the Russian Federation starting October, 2011.<ref>http://www.rg.ru/2011/10/19/narko-dok.html</ref>
 
The NBOMe series of psychoactives became controlled in the Russian Federation starting October, 2011.<ref>http://www.rg.ru/2011/10/19/narko-dok.html</ref>
Line 146: Line 137:
 
The UK Home Office announced that 25I-NBOMe would be made a class A drug on 10th June 2014 alongside every other N-benzyl phenethylamines.<ref>http://www.legislation.gov.uk/ukdsi/2014/9780111110904</ref>
 
The UK Home Office announced that 25I-NBOMe would be made a class A drug on 10th June 2014 alongside every other N-benzyl phenethylamines.<ref>http://www.legislation.gov.uk/ukdsi/2014/9780111110904</ref>
  
== America ==  
+
=== America ===  
  
 
25i-NBOMe, 25b-NBOMe, and 25c-NBOMe were emergency scheduled by the DEA on Novemeber 15, 2013<ref>http://www.justice.gov/dea/divisions/hq/2013/hq111513.shtml</ref>
 
25i-NBOMe, 25b-NBOMe, and 25c-NBOMe were emergency scheduled by the DEA on Novemeber 15, 2013<ref>http://www.justice.gov/dea/divisions/hq/2013/hq111513.shtml</ref>
  
= Images =
+
== Links ==
 
+
<gallery mode="packed-hover" heights="150px">
+
Image:25b.jpg|''25B-NBOMe''
+
Image:25c.jpg|''25C-NBOMe''
+
Image:25i.jpg|''25I-NBOMe''
+
</gallery>
+
 
+
= Links =
+
  
 
[https://en.wikipedia.org/wiki/NBOMe Wikipedia]
 
[https://en.wikipedia.org/wiki/NBOMe Wikipedia]
Line 166: Line 149:
 
[http://www.reddit.com/r/Drugs/comments/14wua3/rdrugs_faq_series_nbome_series_aka_25xnbome/?sort=top /r/Drugs FAQ]
 
[http://www.reddit.com/r/Drugs/comments/14wua3/rdrugs_faq_series_nbome_series_aka_25xnbome/?sort=top /r/Drugs FAQ]
  
= References =
+
== References ==
  
 
<references />
 
<references />
Line 172: Line 155:
 
[[Category:Psychedelic]]
 
[[Category:Psychedelic]]
 
[[Category:Drugs]]
 
[[Category:Drugs]]
 +
[[Category:Research Chemical]]

Latest revision as of 16:33, 2 April 2019

25C-NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. tabs dosed at 1mg each.

These chemicals have nearly no history of human use prior to 2010 when they first became available online, and very little is known about this group of compounds. They should only be used with extreme caution. It's strongly recommended to not take more than 1500 µg of any substance of the NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. family, as there have been multiple deaths from people taking just 2-3 blotters.

Dosage

Effects have been reported to vary wildly between people (example: person A gets a 4-hour body high with barely any visual aspects, while person B gets a >12 hour DOB-like trip with an intense visual aspect). Drugs affect all users differently, but this unusually wide range of reported effects is down, in part, to users being unable to accurately distinguish between members of the NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. series, and misrepresentation of doses - a single tab regularly yields between 500ug and 2000ug of the substance.

NBOMesN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. were initially thought to be orallyRoute of administration in which the subject swallows a substance. inactive, meaning they wouldn't work if swallowed. However, this is not the case for all NBOMesN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. per se; certain NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. salts do have an observed oral bioavailabilityThe fraction of an administered dose that is absorbed into a living system., with little known about the oral bioavailabilityThe fraction of an administered dose that is absorbed into a living system. of NBOMesN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. in their freebase form. Therefore, when a substance might be an NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines., discard the blotter entirely rather than swallowing it, if you do not wish to risk being under the influence of an NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines.. Oral administrationRoute of administration in which the subject swallows a substance. is relatively uncommon and thus undocumented, presumably as a result of the existing confusion about the oral bioavailabilityThe fraction of an administered dose that is absorbed into a living system. of NBOMesN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines.. Sublingual administrationRoute of administration in which the subject places a substance under the tongue. is the most common, but buccal administrationRoute of administration in which the subject places a substance against their gums or other oral mucosa. is recommended if you wish to avoid the generally bitter taste of NBOMesN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines..

The doses of NBOMesN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. remain a controversial subject, as deaths have been reported at doses that were previously assumed acceptable. Please use caution, and in any case, do not exceed 1500µg!

25B-NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines.

Sublingual
Threshold 100ug
Light 100-300ug
Common 350-500ug
Strong 500-700ug+
Insufflated
Threshold 50ug
Light 50-200ug
Common 200-350ug
Strong 350-500+

Dosages from TripSit Factsheets

25C-NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines.

Sublingual
Light 100-300 μg
Common 300-800 μg
Strong 800+ μg

25I-NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines.

Sublingual
Light 200-500 μg
Common 500-750 μg
Strong 700-1000+ μg
Insufflated
Light 100-400 μg
Common 400-700 μg
Strong 700+ μg

Duration

Sublingual
Onset 15-45 minutes
Total 4-11 hours
Insufflated
Onset 0-10 minutes
Total 3-8 hours

Effects

Positive

  • Strong open and closed eye visuals, including trails, color shifts, brightening, etc.
  • Mood lift
  • Euphoria
  • Mental and physical stimulation
  • Increase in associative & creative thinking
  • Increased awareness & appreciation of music
  • Life-changing spiritual experiences
  • Erotic, sexual thoughts and sensations
  • Feelings of love and empathy

Neutral

  • General change in consciousness
  • Pupil dilation
  • Difficulty focusing
  • Unusual body sensations (facial flushing, chills, goosebumps, body energy)
  • Change in perception of time, time dilation
  • Slight increase in heart rate
  • Yawning, especially when coming up

Negative

Likelihood of negative side effects increases with higher doses.

  • Confusion
  • Looping
  • Scrambled communication
  • Nausea
  • Vasoconstriction
  • Insomnia
  • Looping, recursive, out of control thinking
  • Paranoia, fear, and panic
  • Unwanted and overwhelming feelings
  • Unwanted life-changing spiritual experiences

After effects

  • Afterglow
    • An afterglow may be present until a day after use, sometimes more depending on the individual.
  • Long term effects
    • A relatively high rate of HPPD has been reported (all anecdotal data!) after the use of the NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. chemicals.

Harm Reduction

NBOMesN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. are considered less safe than many psychedelics due their heavy physical effects on the body, and as recreational dosages tend to overlap with what have been fatal dosages. Even so, many reports of death by an NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. chemical involve mislabeling of the drug, sometimes by the distributor (example: someone insufflates 20mg of 25I-NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. because he/she thought it was 2C-I). Mislabeling or misweighing can easily lead to extrememely dangerous, sometimes lethal, situations. Administration of an NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. in its powder form (either insufflated or otherwise) is strongly discouraged, as the potency is far greater than the accuracy of most scales.

Furthermore, due to the physical strain the drug causes one should not use it if there are any pre-existing heart conditions.

See Psychedelic Harm Reduction for general information.

Images


Legal status

Europe

The NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. series of psychoactives became controlled in the Russian Federation starting October, 2011.[1]

The UK Home Office announced that 25I-NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. would be made a class A drug on 10th June 2014 alongside every other N-benzyl phenethylamines.[2]

America

25i-NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines., 25b-NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines., and 25c-NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. were emergency scheduled by the DEA on Novemeber 15, 2013[3]

Links

Wikipedia

Erowid

/r/Drugs FAQ

References

  1. http://www.rg.ru/2011/10/19/narko-dok.html
  2. http://www.legislation.gov.uk/ukdsi/2014/9780111110904
  3. http://www.justice.gov/dea/divisions/hq/2013/hq111513.shtml

Top Contributors